Pfizer's axitinib fails in a Phase III pancreatic cancer trial
This article was originally published in Scrip
Executive Summary
Pfizerhas ended a first-line Phase III trial of its investigational anti-angiogenic drug axitinib, its next big cancer drug hope, in advanced pancreatic cancer after an interim analysis found that it would not improve overall survival.